Traditional antidepressants require many weeks to reveal their therapeutic effects. However,
the widely replicated observation that a single subanesthetic dose of the N-methyl-D …

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder.
Traditional antidepressants are of limited efficacy and take weeks to months to yield full …

The molecular mechanisms underlying major depressive disorder remain poorly
understood, and current antidepressant treatments have many shortcomings. The recent …

The therapeutic onset of traditional antidepressants is delayed by several weeks and many
depressed patients fail to respond to treatment altogether. In contrast, subanesthetic …

Newer antidepressants are needed for the many individuals with major depressive disorder
(MDD) that do not respond adequately to treatment and because of a delay of weeks before …

Recent clinical studies have demonstrated that a single subpsychotomimetic dose of
ketamine, an ionotropic glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist …

Recent reports of a rapid antidepressant effect of the glutamate N‐methyl‐d‐aspartate
(NMDA) receptor antagonist ketamine, even in treatment‐resistant populations, have …

Ketamine is the prototype for a new generation of glutamate-based antidepressants that
rapidly alleviate depression within hours of treatment. Over the past decade, there has been …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

What is known and objective Abundant clinical data now confirm that ketamine produces a
remarkable rapid‐onset antidepressant effect–hours or days–in contrast to the delayed …